4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-23-046462
Chief R&D Officer sold 9,703 shares at $0.78 ($7,568)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2023-08-16 | Sale | −9,703 | $0.78 | $7,568 | 283,685 | D: show line 1 in the form |
| Open-market sales · 9,703 sh · avg $0.78 · $7,568 | |||||||
Loading xslF345X05/doc4.xml…